Healthcare Industry News: UCB
News Release - May 25, 2006
UCB Sells to Adams Respiratory Therapeutics OTC Delsym(R) 12-Hour Cough Suppressant LiquidsBRUSSELS, BELGIUM--(Healthcare Sales & Marketing Network)--May 25, 2006 -- UCB S.A. announces today that it has reached an agreement with Adams Respiratory Therapeutics Inc. (NasdaqNM:ARXT ) to sell DelsymŪ (dextromethorphan polistirex), an over-the-counter (OTC) 12-hour liquid cough suppressant. In addition, the two companies have entered into a separate agreement for the licensing of the 12-hour liquid technology.
The financial terms of the agreement consist of a one-time, upfront payment to UCB of 122 million U.S. dollars, royalties for a period of 5 years based on sales and a standard manufacturing supply agreement with a "cost-plus" structure.
"This transaction is another step taken by UCB in its strategy to focus on research-driven innovation and novel therapeutic solutions for severe and chronic diseases treated by specialist physicians," declared Roch Doliveux, Chief Executive Officer of UCB.
DelsymŪ is a cough medicine that doctors and pharmacists have recommended for years in the United States. It is the only OTC liquid cough suppressant than can deliver 12 hours of cough relief in a single dose. DelsymŪ is made with a patented time-release formulation that allows the cough suppressant dextromethorphan to be available in the body over a 12-hour period.
About Adams Respiratory Therapeutics, Inc.
Adams (www.adamsrt.com) is a U.S.-based specialty pharmaceutical company focused on the late-stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders.
UCB (www.ucb-group.com) is a leading global biopharmaceutical company dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories. Employing 8,500 people in 40 countries, UCB achieved revenues of EUR2.3 billion in 2005. UCB is listed on the Euronext Brussels Exchange. Worldwide headquarters are located in Brussels, Belgium.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsUCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer's Disease
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
UCB Acquires Engage Therapeutics: Staccato(R) Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy